Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome

Table 4

Modification of PSA failure rates according to stage, at 10 years (unless specified).

First author, yr

𝑛

Cohort Years

PSA fail criterion ng/mL

% PSM, overall

% biochemical failure rate

% biochemical failure rate with PSM by stage

PSM

NSM

𝑃 value HR

pT2

𝑃 value, HR

pT3a

𝑃 value, HR

Stage pT3b

𝑃 value, HR

Williams; 2010 [7]

4240

2004–2006

—

19.4

No f/u

14.9

42

—

Ploussard; 2010 [34]

1943

2000–2008

>0.2

25.6

54.2

29.9

𝑃<.001, HR 2.6

𝑃<.001, HR 3.81

𝑃=.001, HR 2.09

𝑃=.1, HR 1.46

Budäus; 2010 [35]

4490

1992–2008

≥0.1

18.9

—

17 versus 5

HR 2.9

38 versus 26

HR 1.9

71 versus 53,

HR 1.4

Brimo; 2010 [36]

108^†

1995–2008

≥0.2

Inclusion criterion^†

—

—

58

—

Hsu; 2010 [37]

164

1977–2004

≥0.2

48.2; (all cT3)

—

—

57%, HR 4.1, 𝑃=.03

Ficarra; 2009 [38]

322*

2005–2008

≥0.2

29.5

6.2

1.8

𝑃<.001 (at 12 mo.)

10.6

57.5

𝑃<.001, HR=11.8

72.2

Kwak; 2010 [39]

266

1995–2007

≥0.2

18.5

52.6

8

𝑃<.0001

29.3 versus 7.3^$

𝑃<.0001

51 versus 10.5

𝑃=.04; HR 1.4,

—

Hashimoto; 2008 [40]

238**

1985–2005

≥0.2

34.4

38.4

19.3

𝑃<.001

HR=1

𝑃=.033 HR 3.36,

𝑃=.002, HR 7.13,

Chuang; 2007 [41]

135**

1993–2004

≥0.2

—

—

28.7 versus 3.3

𝑃<.0001

Focal EPE 21.4% versus 10.3%, 𝑃=.02,

Ext EPE 41.5% versus 26%, 𝑃<.0001

Orvieto; 2006 [4]

996

1994–2004

≥0.1

8.8 (all); pT2 1.7, pT3a 24.9, pT3b 27.1

35

7.8

𝑃<.001, HR 3.27

𝑃<.001, HR=1.7

𝑃=.011, HR 3.6

𝑃=.19, HR 6.5

Karakiewicz; 2005 [42]

5831

1983–2000

≥0.1–≥0.4

26.7

63.9

29.9

𝑃=.001, HR 3.66

63 versus 30

𝑃<.001

—

—

Swindle; 2005 [43]

1369

1983–2000

≥0.4

12.9 (all); pT2 6.8, pT3 23

42

19

𝑃=.002, HR 1.52

38.6 versus 19.6

𝑃<.001

74.9% versus 53.8%, 𝑃<.001

*Robotic only.
**Study used 5-year biochemical recurrence.
^†Restricted to GS=7, stage pT3a, and PSM.
^$If there is capsular incision, versus no capsular incision.